Drugs / GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03636906 | Apr 2019 → Jan 2020 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK's meningococcal group A, C, W-135 and Y conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03636906 ↗ |
| Modality | Vaccine | “GSK's meningococcal group A, C, W-135 and Y conjugate vaccine” NCT03636906 ↗ |
| Route | Intramuscular | “2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly” NCT03636906 ↗ |